Effects of Telmisartan compared with Candesartan on ischemic cardiovascular events in high-risk hypertensive patients: a multi-center, prospective, randomized, open-labeled, blinded endpoints trial - Effects of Telmisartan on ischemic cardiovascular events in high-risk hypertensive patients: a multi-center, prospective, randomized, open-labeled, blinded endpoints trial

Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine0 个研究点目标入组 1,500 人开始时间: 2009年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The exclusion criteria are set as follow: 1.History of worsening of heart failure within the preceding 6 months 2.Planned elective percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the anteceding 3 months 3.History of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the preceding 12 months 4.History of percutaneous hind limb angioplasty (PTA) or bypass grafting within the preceding 6 months 5.History of cerebral infarction, cerebral hemorrhage within the past 6 months 6.Congenital heart disease 7.Uncontrolled hypertension on treatment (eg, BP>180/110 mmHg) 8.Pregnant women or women of childbearing potential 9.Hepatic dysfunction (AST or ALT >100IU/L) 10.Renal impairment (serum creatinine level >2.0 mg per 100 ml) 11.Known hypersensitivity or intolerance to ARB

发起方

Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine